Assessment of eyesight related outcome and quality of life during course of treatment with ANTI-VEGF injection in diabetic patients.

Not Applicable

• Conditions: Health Condition 1: H30-H36- Disorders of choroid and retinaHealth Condition 2: H358- Other specified retinal disorders

• Registration Number: CTRI/2024/07/070519
• Lead Sponsor: Ramanpreet Kaur

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

Patients with center involving diabetic macular edema requiring anti-VEGF injections

Patients who are already undergoing treatment with intravitreal anti-VEGF injections

Exclusion Criteria

Patients with media opacities due to dense cataract , vitreous hemorrhage etc in whom it is difficult to assess posterior segment

Patients with recent stroke less than 3 months who cannot be injected anti-VEGF

Patient with other chronic comorbidities example inability to walk , hearing loss or visual loss due to causes other than DME that may affect quality of life

Patients undergoing other intravitreal injections like steroids

Patients who are not able to have adequate hearing and sight cognition to be able to complete interview questions

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1 Visual acuity (log Mar scale) in patients before undergoing intravitreal anti VEGF injections in diabetic macular edema <br/ ><br>2. The quality of life (NEI VFQ25 )in patients undergoing intravitreal anti-VEGF injections in diabetic macular edema <br/ ><br>3. Visual acuity (log Mar scale)in patients with diabetic macular edema after intra vitreal anti-VEGF injections at 4 weeks,8 weeks,12 weeks.Timepoint: Visual acuity and NEIVFQ-25 score - baseline, 4 weeks, 8 weeks, 12 weeks after anti-VEGF injection. <br/ ><br>

Secondary Outcome Measures

Name	Time	Method
Visual acuity (log Mar scale)in patients with diabetic macular edema after intra vitreal anti-VEGF injections at 4 weeks,8 weeks,12 weeks.Timepoint: Visual acuity (log Mar scale)in patients with diabetic macular edema after intra vitreal anti-VEGF injections at 4 weeks, 8 weeks,12 weeks